Biochem/physiol Actions

CBP BRD (CREB binding protein bromodomain) inhibition serves as an effective therapeutic target for Parkinson’;s disease. The inhibition is followed by negative regulation of a number of macrophage inflammatory genes. It also downregulates G-protein signaling 4 mRNA.

ISOX-INACT is an inactive control probe for the highly-selective inhibitor of the bromodomain of CREB binding protein (CBP BRD) PF-CBP1.

Legal Information

Pfizer is a registered trademark of Pfizer, Inc.

Sold for research purposes under agreement from Pfizer Inc.

Other Notes

This compound was developed by Pfizer for Gene Regulation research. To learn more about Sigma′s partnership with Pfizer and view other authentic, high-quality Pfizer compounds, visit sigma.com/bsm-pfizer.

Packaging

5, 25 mg in glass bottle